1-(3-甲基-丁基)-吡咯 | 13679-79-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-(3-甲基-丁基)-吡咯
• 英文名称: N-Isoamylpyrrol
• 英文别名: 1-Isopentyl-1H-pyrrol；1-(3-methyl-butyl)-pyrrole；1-isopentyl-pyrrole；1-Isopentyl-pyrrol；1-(3-Methylbutyl)pyrrole
• CAS: 13679-79-3
• 化学式: C₉H₁₅N
• mdl: MFCD12187086
• 分子量: 137.225
• InChiKey: QNFYLUDPMZVIOW-UHFFFAOYSA-N

物化性质

• 沸点：
  187.1±9.0 °C(Predicted)
• 密度：
  0.86±0.1 g/cm3(Predicted)
• LogP：
  3.233 (est)
• 保留指数：
  1378;1392

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(3-甲基-丁基)-吡咯 在 copper bronze 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and structure–Activity relationships of aroylpyrrole alkylamide bradykinin (B2) antagonists

  摘要：

  The synthesis and structure-activity relationships of a novel series of aroylpyrrole alkylamindes as potent selective bradykinin 132 receptor antagonists are described. Several members of this series display nanomolar affinity at the B-2 receptor and show activity in an animal model of antinociception. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00104-5
• 作为产物：
  描述：

  吡咯 在 氢化钾 、 苯 作用下， 生成 1-(3-甲基-丁基)-吡咯
  参考文献：
  名称：

  Ochiai; Tsuda, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1934, vol. 54, p. 652,663

  摘要：

  DOI：

文献信息

• SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS
  申请人：Purdue Pharma L.P.

  公开号：US20150057300A1

  公开（公告）日：2015-02-26

  The present disclosure provides substituted piperidines or pyrrolidines having Formula IA: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2a , R 2b , R 6 , A, X, m and n are defined as set forth in the specification. In certain embodiments, Compounds of the present disclosure are useful for treating pain. The present disclosure is also directed to the use of Compounds of the present disclosure to treat a disorder responsive to blockade of one or more sodium channels.

  本公开提供具有公式IA的取代哌啶或吡咯烷： 及其药用可接受的盐和溶剂化物，其中R1，R2a，R2b，R6，A，X，m和n按说明书定义。在某些实施方式中，本公开的化合物可用于治疗疼痛。本公开还涉及使用本公开的化合物来治疗对阻断一个或多个钠通道有反应的疾病。
• PYRIDINES AND PYRIMIDINES AND USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20170008882A1

  公开（公告）日：2017-01-12

  The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W 1 , W 2 , W 3 , and R 5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.

  本公开提供了Formula I的吡啶和嘧啶以及其药用可接受的盐和溶剂化合物：其中A、G、W1、W2、W3和R5如规范中所述。本公开还提供了Formula I化合物及其药用可接受的盐和溶剂的用途。在某些实施例中，本公开的化合物对治疗疼痛有用。在另一实施例中，本公开的化合物对治疗对钠通道阻滞有反应的疾病，或缓解该疾病的症状有用。
• RENIN INHIBITORS
  申请人：Gwaltney Stephen L.

  公开号：US20100137310A1

  公开（公告）日：2010-06-03

  The invention provides compounds, pharmaceutical compositions, kits, method of preparing, and method of using the compounds which exhibit renin and other S9 proteases activities and consist of the formula:—wherein the variables are as defined herein.

  这项发明提供了一种具有肾素和其他S9蛋白酶活性的化合物、药物组合物、试剂盒、制备方法和使用该化合物的方法，其化学式为：—其中变量如本文所定义。
• BORATE-BASED BASE GENERATOR, AND BASE-REACTIVE COMPOSITION COMPRISING SUCH BASE GENERATOR
  申请人：WAKO PURE CHEMICAL INDUSTRIES, LTD.

  公开号：US20160340374A1

  公开（公告）日：2016-11-24

  An object of the present invention is to provide a compound which is capable of attaining a composition having high storage stability without reacting with a base-reactive compound, even in the case of storage for a long period of time in a mixed state with the base-reactive compound, such as an epoxy-based compound, as well as capable of generating a strong base (guanidines, biguanides, phosphazenes or phosphoniums) by irradiation of light (active energy rays) or heating; a base generator comprising the compound; and a base-reactive composition comprising the base generator and the base-reactive compound. The present invention relates to the compound represented by the general formula (A); the base generator comprising the compound; and the base-reactive composition comprising the base generator and the base-reactive compound. (wherein R 1 represents an alkyl group; an arylalkynyl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; an alkenyl group; a 2-furylethynyl group; a 2-thiophenylethynyl group; or a 2,6-dithianyl group; R 2 to R 4 each independently represent an alkyl group; an arylalkynyl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; the aryl group which may be substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; a furanyl group; a thienyl group; or an N-alkyl-substituted pyrrolyl group; Z + represents an ammonium cation having a guanidinium group, a biguanidium group or a phosphazenium group, or a phosphonium cation.)

  本发明的目的是提供一种化合物，能够在与碱反应性化合物混合状态长时间存储的情况下，仍能获得具有高储存稳定性的组合物，而不与碱反应性化合物发生反应，同时还能通过光照（活性能量射线）或加热产生强碱（胍胺、双胍胺、磷氮烷或磷銨）；包括该化合物的碱发生器；以及包括该碱发生器和碱反应性化合物的碱反应性组合物。本发明涉及由通式（A）表示的化合物；包括该化合物的碱发生器；以及包括该碱发生器和碱反应性化合物的碱反应性组合物。（其中R1代表烷基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基炔基；烯基；2-呋喃基炔基；2-噻吩基炔基；或2,6-二硫基基；R2到R4各自独立地代表烷基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基炔基；可能被卤素原子、烷基、烷氧基或烷硫基取代的芳基；呋喃基；噻吩基；或N-烷基取代的吡咯基；Z+代表具有胍胺基团、双胍胺基团或磷氮烷基团的铵阳离子，或磷銨阳离子。）
• PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE
  申请人：Heffernan Michele L. R.

  公开号：US20110034434A1

  公开（公告）日：2011-02-10

  The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective.

  该发明涉及融合杂环抑制剂的前药，用于治疗疾病和病况的方法，其中在哺乳动物主体的神经系统中调节D-氨基酸氧化酶活性、D-丝氨酸水平、D-丝氨酸氧化产物和NMDA受体活性是有效的。